Back to results
US 10,881,664 B2Granted
Methods for treating EGFR mutant cancers
AssigneeNovartis AG
InventorsNgocDiep Le, Gerald Lelais, Yong Jia
Life of this patent
Estimating the term…
Abstract
Methods for the treatment of EGFR mutated cancer. For example, treatment of non-small cell lung cancer (NSCLC) with activating EGFR mutations (e.g., L858R and ex19del) the acquired or resistant “gatekeeper” T790M mutation, or any combination of these mutations.
Claims8
A method of treating NSCLC in a patient comprising administering to the patient a therapeutically effective amount of (R,E)-N-(7-chloro-1-(1-(4-(dimethylamino)but-2-enoyl)azepan-3-yl)-1Hbenzo[d]imidazol-2-yl)-2-methylisonicotinamide (Compound A), or a pharmaceutically acceptable salt thereof,
- wherein the NSCLC harbors an EGFR exon 20 insertion,
- and wherein Compound A is administered in a dose ranging from 75 mg to 225 mg daily.
Dependencies are inferred from the claim text.